Intraocular pressure (IOP) reduction is currently the only evidence‐based treatment strategy
for glaucoma. However, IOP control in some individuals is challenging. Despite optimal …

Glaucoma, a progressive optic neuropathy characterized by retinal ganglion cell
degeneration and visual field loss, is the leading cause of irreversible blindness worldwide …

Glaucoma is a neurodegenerative disease that affects primarily the retinal ganglion cells
(RGCs). Increased intraocular pressure (IOP) is one of the major risk factors for glaucoma …

Purpose: The eye is currently at the forefront of translational medicine and therapeutics.
However, despite advances in technology, primary open-angle glaucoma remains the …

Glaucoma is the second leading cause of blindness worldwide and is most notably
characterized by progressive optic nerve atrophy and advancing loss of retinal ganglion …

The maintenance of vision, through prevention and attenuation of neuronal injury in
glaucoma, forms the basis of current clinical practice. Currently, the reduction of intraocular …

Glaucoma is a common, complex, multifactorial neurodegenerative disease characterized
by progressive dysfunction and then loss of retinal ganglion cells, the output neurons of the …

Glaucoma, a disease of the optic nerve and retina, causes blindness in millions of people
worldwide. Currently available therapies for this disease only attempt to reduce intraocular …

Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal
ganglion cells and their axons. Lowering of intraocular pressure (IOP) is currently the only …

Background: Glaucoma is characterized as a neuropathic disease that causes progressive
degeneration of retinal ganglion cells (RGCs) in the retina, resulting in irreversible loss of …